全球首个可皮下注射的C5补体抑制剂在华获批，用于治疗全身型重症肌无力

Core Viewpoint - The approval of Zilucoplan, the world's first subcutaneously injectable C5 complement inhibitor, marks a significant advancement in the treatment of generalized myasthenia gravis in adults with AChR antibody positivity in China [1] Group 1: Product Approval - The Chinese National Medical Products Administration has granted marketing authorization for Zilucoplan [1] - Zilucoplan is intended to be used in conjunction with conventional treatment medications [1] Group 2: Market Significance - This approval represents a milestone as it is the first and only subcutaneous C5 complement inhibitor available globally [1]